Begin main content

Reports

We found 5539 result(s)

insulin degludec + liraglutide (Xultophy)

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: insulin degludec + liraglutide
Indications: Diabetes mellitus, Type 2

  • Brand Name: Xultophy
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0599-000
  • Project Status: Active
  • Submission Type: NewCombination

patisiran (Onpattro)

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: patisiran
Indications: Polyneuropathy in hereditary transthyretin-mediated amyloidosis

  • Brand Name: Onpattro
  • Manufacturer: Alnylam Netherlands BV
  • Project Number: SR0598-000
  • Project Status: Active
  • Submission Type: New

baricitinib (Olumiant )

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: baricitinib
Indications: Arthritis, Rheumatoid

  • Brand Name: Olumiant
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0597-000
  • Project Status: Active
  • Submission Type: New

risankizumab (Skyrizi)

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: risankizumab
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: Skyrizi
  • Manufacturer: AbbVie Corporation
  • Project Number: SR0583-000
  • Project Status: Active
  • Submission Type: New

isavuconazole (Cresemba)

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: isavuconazole
Indications: Treatment of invasive aspergillosis and mucormycosis

  • Brand Name: Cresemba
  • Manufacturer: AVIR Pharma Inc.
  • Project Number: SR0586-000
  • Project Status: Active
  • Submission Type: New

Latanoprostene bunod (Vyzulta )

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: latanoprostene bunod
Indications: Open-angle glaucoma or ocular hypertension

  • Brand Name: Vyzulta
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0590-000
  • Project Status: Active
  • Submission Type: New

telotristat (Xermelo)

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: telotristat
Indications: carcinoid syndrome

  • Brand Name: Xermelo
  • Manufacturer: Ipsen Biopharmaceuticals Canada Inc.
  • Project Number: SR0580-000
  • Project Status: Active
  • Submission Type: New

Prolastin-C for the Treatment of Alpha1-Antitrypsin Deficiency: A Review of Economic Evaluations

Last Updated: May 22, 2019
Result type: Reports
Product Line: Technology Review

Prolastin-C is an alpha1-proteinase inhibitor (A1-PI) that received its Notice of Compliance in Canada in 2010; this product replaced an older A1-PI formulation called Prolastin. Other A1-PI products available globally include Aralast and Respreeza/Zemaira. Patients with alpha1-antitrypsin (AAT) deficiency have low AAT levels. Intravenous infusi...

  • Project Number: HE0013-000

doravirine (Pifeltro )

Last Updated: May 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: doravirine
Indications: HIV-1

  • Brand Name: Pifeltro
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0582-000
  • Project Status: Active
  • Submission Type: New